These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8438449)

  • 1. Effects of brequinar sodium on cynomolgus monkeys: immunosuppression and pharmacokinetics.
    Jaffee BD; Jones EA; Zajac I; Magolda RL; Cramer DV; Makowka L
    Transplant Proc; 1993 Feb; 25(1 Pt 1):710-1. PubMed ID: 8438449
    [No Abstract]   [Full Text] [Related]  

  • 2. Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro.
    Simon P; Townsend RM; Harris RR; Jones EA; Jaffee BD
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):77-80. PubMed ID: 8390742
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of the in vitro and in vivo immunosuppressive activity of brequinar sodium.
    Eiras-Hreha G; Cramer DV; Cajulis E; Cosenza C; Mills L; Hough K; Frankland M; Chapman F; Wang H; Zajac I
    Transplant Proc; 1993 Feb; 25(1 Pt 1):708-9. PubMed ID: 8438448
    [No Abstract]   [Full Text] [Related]  

  • 4. Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine.
    Thomson AW; Woo J; Lemster B; Todo S; Fung JJ; Starzl TE
    Transplant Proc; 1993 Feb; 25(1 Pt 1):704-5. PubMed ID: 8438446
    [No Abstract]   [Full Text] [Related]  

  • 5. Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression.
    Chong AS; Gebel H; Finnegan A; Petraitis EE; Jiang XL; Sankary HN; Foster P; Williams JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):747-9. PubMed ID: 8438466
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium.
    Moudgil A; Toyoda M; Wang SJ; Jaffee BD; Cramer DV; Makowka L; Jordan S
    Transplant Sci; 1994 Sep; 4(1):116-8. PubMed ID: 7528627
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoral pharmacokinetics in cynomolgus monkeys: relation to efficacy in renal allografting.
    Schuurman HJ; Hengy JC; Ringers J; Vonderscher J; Schuler W; Jonker M
    Transplant Proc; 1996 Dec; 28(6):3142-4. PubMed ID: 8962218
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium.
    Xu X; Williams JW; Shen J; Gong H; Yin DP; Blinder L; Elder RT; Sankary H; Finnegan A; Chong AS
    J Immunol; 1998 Jan; 160(2):846-53. PubMed ID: 9551920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar.
    Stepkowski SM; Kahan BD
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):29-31. PubMed ID: 8516939
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of L-asparaginase on lymphocyte surface and blastogenesis.
    Fidler IJ; Montgomery PC
    Cancer Res; 1972 Nov; 32(11):2400-6. PubMed ID: 5082588
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium.
    Lemster B; Woo J; Strednak J; Wang SC; Todo S; Starzl TE; Thomson AW
    Transplant Proc; 1992 Dec; 24(6):2845-6. PubMed ID: 1281576
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxicological and pharmacokinetic effects following coadministration of brequinar sodium and cyclosporine to Sprague-Dawley rats.
    Barnes TB; Campbell P; Zajac I; Gayda D
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):71-4. PubMed ID: 8516950
    [No Abstract]   [Full Text] [Related]  

  • 13. Brequinar sodium: monitoring immunosuppressive activity.
    Eiras-Hreha G; Cramer DV; Cosenza C; Chapman FA; Mills L; Cajulis E; Hill D; Jones E; Zajac I; Jaffee B
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):32-6. PubMed ID: 8516940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics.
    Gummert JF; Barten MJ; Sherwood SW; van Gelder T; Morris RE
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1100-12. PubMed ID: 10565830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of reactivation of shigellosis in naturally infected enrofloxacin-treated cynomolgus monkeys after exogenous immunosuppression.
    Black-Schultz L; Coatney RW; Warnick CL; Swif B
    Lab Anim Sci; 1997 Dec; 47(6):602-5. PubMed ID: 9433696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effects of artesunate and other antimalarial agents on the function of human lymphocytes and neutrophils.
    Chen M; Kappel M; Lemnge M; Bygbjerg IC; Theander TG; Kharazmi A
    Transplant Proc; 1994 Dec; 26(6):3172-4. PubMed ID: 7998107
    [No Abstract]   [Full Text] [Related]  

  • 17. Individual and species differences in the in vitro sensitivity to brequinar sodium.
    Eiras-Hreha G; Cramer DV; Cajulis E; Hill D; Frankland M; Hough K; Mills L; Nicholson B; Chapman F; Jaffee B
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):61-4. PubMed ID: 8516947
    [No Abstract]   [Full Text] [Related]  

  • 18. L-asparaginase and alteration of lymphocyte surface. Inhibition of the rat mixed leukocyte interaction.
    Kahn JM; Fidler IJ
    J Med; 1973; 4(4):248-56. PubMed ID: 4272007
    [No Abstract]   [Full Text] [Related]  

  • 19. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation.
    Makowka L; Chapman F; Cramer DV
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):2-7. PubMed ID: 8516937
    [No Abstract]   [Full Text] [Related]  

  • 20. The development of Brequinar as an immunosuppressive drug for transplantation.
    Makowka L; Sher LS; Cramer DV
    Immunol Rev; 1993 Dec; 136():51-70. PubMed ID: 8132203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.